Total Joint Orthopedics lands up to $11 million in growth financing

Total Joint Orthopedics secured a debt facility of up to $11 million to speed up inventory, instrumentation, sales expansion and product development. The Salt Lake City medical device company says the funding will help it scale its joint replacement business while preserving ownership flexibility.

Why it matters: - The financing gives Total Joint Orthopedics fresh capital to push commercial expansion without taking on equity dilution. - The company plans to use the money to expand its footprint in hospitals and ambulatory surgery centers, where joint replacement is shifting more of its business. - The funding also supports product development tied to the company’s Efficiency by Design® platform and next-generation implant pipeline.

What happened: - Total Joint Orthopedics said it secured a growth financing package through a debt facility of up to $11 million. - The company announced the financing on October 21, 2026, in Salt Lake City. - TJO said the capital will help accelerate growth initiatives over the coming months. - The company said the financing expands its banking relationship with Wells Fargo. - TJO said it evaluated equity investment, strategic partnership opportunities and debt financing before choosing debt as the most efficient path.

The details: - TJO plans to expand implant inventory and instrument sets for surgeon customers in hospitals and ambulatory surgery centers. - The company plans to broaden sales channel coverage by adding and strengthening distribution partners in targeted markets. - TJO will continue work on porous and revision Aurum® designs. - The company said its long-term plan is to eliminate cobalt chrome in orthopedic implants. - Aurum® uses a ballistically bonded titanium nitride surface and is designed without the deliberate addition of nickel, cobalt or chromium. - TJO also plans to continue development of a next-generation hip stem for the Platform® Hip System Portfolio. - The company plans to expand additive manufacturing with supply partners to shorten lead times and improve supply chain resilience.

Between the lines: - The financing structure suggests TJO wanted to preserve ownership control while still funding growth. - TJO is leaning on its existing clinical and commercial momentum to support the next phase of expansion. - Christopher E. Pelt, MD, said the company’s approach reduces instrument trays and streamlines workflow in the operating room. - Aaron Hofmann, MD, said the financing will help put TJO’s implant platform in front of more surgeons and patients. - Erin Hofmann said the company chose the structure that best serves surgeons, employees and shareholders.

What's next: - TJO said it will share additional updates on its growth initiatives in the coming months. - The company will exhibit at the AAHKS 2026 Annual Meeting in Grapevine, Texas, from November 5-8. - TJO expects the new capital to support broader distribution, more field inventory and continued technology development. - The company will keep advancing its Efficiency by Design® platform across hip and knee offerings.

The bottom line: - TJO now has the capital and lending support to push harder on commercial growth while continuing to build out its implant portfolio.